New Roche Data To Be Presented At Asco Offers Further Hope For Cancer Patients

BASEL, Switzerland -- Patients with breast or colorectal cancer, two of the world's most common cancers, can expect further treatment advances with Avastin(R) (bevacizumab) and Herceptin(R) (trastuzumab) following new data that is being presented at the 44th American Society of Clinical Oncology (ASCO) annual meeting in Chicago at the end of May. Around 30,000 medical experts will attend the meeting which is the premier event for cancer therapy worldwide. The Roche data will show that Avastin and Herceptin are continuing to offer further hope of improving survival in patients with cancers that are still devastating thousands of lives each year. Breast cancer - Avastin: Late-breaking Phase III data from the AV...